Details of the Drug

General Information of Drug (ID: DM4W9B3)

Drug Name
Fosamprenavir
Synonyms
Telzir; Amprenavir phosphate; Fosamprenavir [INN]; GW 433908; GW433908; VX 175; Fosamprenavir (INN); Lexiva (TM); Lexiva (TN); Telzir (TN); Telzir(TM); VX-175; GW433908A (*Sodium Salt*); GW433908G (*Calcium Salt*); [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, C-((3S)-tetrahydro-3-furanyl) ester; ((3S)Oxolan-3-yloxy)-N-((1S,2R)-3-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-1-benzyl-2-(phosphonooxy)propyl)carboxamide; (3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [1]
Therapeutic Class
Anti-HIV Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 585.6
Topological Polar Surface Area (xlogp) 1.8
Rotatable Bond Count (rotbonds) 14
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 11
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Elimination
0% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 7.7 hours [3]
Metabolism
The drug is metabolized via the liver [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 67.80681 micromolar/kg/day [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.31 mg/mL [2]
Chemical Identifiers
Formula
C25H36N3O9PS
IUPAC Name
[(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate
Canonical SMILES
CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)OP(=O)(O)O)S(=O)(=O)C3=CC=C(C=C3)N
InChI
InChI=1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1
InChIKey
MLBVMOWEQCZNCC-OEMFJLHTSA-N
Cross-matching ID
PubChem CID
131536
ChEBI ID
CHEBI:82941
CAS Number
226700-79-4
DrugBank ID
DB01319
TTD ID
D0F5MT
VARIDT ID
DR01274
INTEDE ID
DR0745
ACDINA ID
D00292

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Protease (HIV PR) TT5FNQT POL_HV1B1 Inhibitor [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Fosamprenavir
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
MK-1439 DM215WE Minor Decreased metabolism of Fosamprenavir caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Fostemsavir DM50ILT Moderate Decreased metabolism of Fosamprenavir caused by Fostemsavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Fosamprenavir caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Dolutegravir DMCZGRE Major Increased metabolism of Fosamprenavir caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Maraviroc DMTL94F Major Decreased metabolism of Fosamprenavir caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [39]
Coadministration of a Drug Treating the Disease Different from Fosamprenavir (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Decreased metabolism of Fosamprenavir caused by Ivosidenib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [40]
Midostaurin DMI6E0R Moderate Decreased metabolism of Fosamprenavir caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [41]
Arn-509 DMT81LZ Moderate Increased metabolism of Fosamprenavir caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [42]
Gilteritinib DMWQ4MZ Moderate Decreased metabolism of Fosamprenavir caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [43]
Oliceridine DM6MDCF Major Decreased metabolism of Fosamprenavir caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [44]
Ivabradine DM0L594 Major Decreased metabolism of Fosamprenavir caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [37]
Dronedarone DMA8FS5 Major Decreased metabolism of Fosamprenavir caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [37]
Bedaquiline DM3906J Moderate Decreased metabolism of Fosamprenavir caused by Bedaquiline mediated inhibition of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [45]
Troleandomycin DMUZNIG Minor Decreased metabolism of Fosamprenavir caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [46]
Cariprazine DMJYDVK Major Decreased metabolism of Fosamprenavir caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [47]
Erdafitinib DMI782S Major Decreased metabolism of Fosamprenavir caused by Erdafitinib mediated inhibition of CYP450 enzyme. Bladder cancer [2C94] [48]
Pexidartinib DMS2J0Z Major Decreased metabolism of Fosamprenavir caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [49]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Fosamprenavir caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [50]
HKI-272 DM6QOVN Major Decreased metabolism of Fosamprenavir caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [51]
LY2835219 DM93VBZ Moderate Decreased metabolism of Fosamprenavir caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [52]
Tucatinib DMBESUA Moderate Decreased metabolism of Fosamprenavir caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [53]
Palbociclib DMD7L94 Major Decreased metabolism of Fosamprenavir caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [54]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Fosamprenavir caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Trastuzumab Emtansine DMU1LXS Moderate Decreased metabolism of Fosamprenavir caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Macitentan DMP79A1 Major Decreased metabolism of Fosamprenavir caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [55]
Vilanterol DMF5EK1 Moderate Decreased metabolism of Fosamprenavir caused by Vilanterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [56]
Revefenacin DMMP5SI Moderate Decreased clearance of Fosamprenavir due to the transporter inhibition by Revefenacin. Chronic obstructive pulmonary disease [CA22] [57]
Indacaterol DMQJHR7 Minor Decreased metabolism of Fosamprenavir caused by Indacaterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [58]
Levomilnacipran DMV26S8 Major Decreased metabolism of Fosamprenavir caused by Levomilnacipran mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [59]
Regorafenib DMHSY1I Moderate Decreased metabolism of Fosamprenavir caused by Regorafenib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [37]
Drospirenone DM1A9W3 Major Decreased metabolism of Fosamprenavir caused by Drospirenone mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [37]
Ulipristal DMBNI20 Minor Decreased metabolism of Fosamprenavir caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [43]
Osilodrostat DMIJC9X Major Decreased metabolism of Fosamprenavir caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [43]
Ivacaftor DMZC1HS Major Decreased metabolism of Fosamprenavir caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [37]
MK-8228 DMOB58Q Moderate Decreased metabolism of Fosamprenavir caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [60]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Fosamprenavir caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [37]
Vilazodone DM4LECQ Major Decreased metabolism of Fosamprenavir caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [61]
Polatuzumab vedotin DMF6Y0L Major Decreased metabolism of Fosamprenavir caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [62]
Ospemifene DMC4GEI Moderate Decreased metabolism of Fosamprenavir caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [63]
Cenobamate DMGOVHA Moderate Increased metabolism of Fosamprenavir caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [42]
Stiripentol DMMSDOY Moderate Decreased metabolism of Fosamprenavir caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [43]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Fosamprenavir caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [64]
Lacosamide DMVM6QR Moderate Decreased metabolism of Fosamprenavir caused by Lacosamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [37]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Fosamprenavir caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [42]
Cannabidiol DM0659E Minor Decreased metabolism of Fosamprenavir caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [43]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Fosamprenavir caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [65]
Tazemetostat DMWP1BH Major Decreased metabolism of Fosamprenavir caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [66]
Solifenacin DMG592Q Major Decreased metabolism of Fosamprenavir caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [37]
Mirabegron DMS1GYT Minor Decreased metabolism of Fosamprenavir caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [67]
Dexlansoprazole DM1DBV5 Moderate Decreased absorption of Fosamprenavir due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [68]
Avapritinib DMK2GZX Major Decreased metabolism of Fosamprenavir caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [43]
Colchicine DM2POTE Major Decreased metabolism of Fosamprenavir caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [69]
ABT-450 DMFW860 Moderate Decreased metabolism of Fosamprenavir caused by ABT-450 mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [43]
Simeprevir DMLUA9D Major Decreased metabolism of Fosamprenavir caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [37]
Daclatasvir DMSFK9V Moderate Decreased metabolism of Fosamprenavir caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [37]
GS-9857 DMYU6P5 Moderate Decreased clearance of Fosamprenavir due to the transporter inhibition by GS-9857. Hepatitis virus infection [1E50-1E51] [70]
Brentuximab vedotin DMWLC57 Moderate Decreased metabolism of Fosamprenavir caused by Brentuximab vedotin mediated inhibition of CYP450 enzyme. Hodgkin lymphoma [2B30] [43]
BMS-201038 DMQTAGO Major Decreased metabolism of Fosamprenavir caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [37]
Aliskiren DM1BV7W Moderate Decreased metabolism of Fosamprenavir caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [71]
Levamlodipine DM92S6N Moderate Decreased metabolism of Fosamprenavir caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [71]
Tolvaptan DMIWFRL Major Decreased metabolism of Fosamprenavir caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [37]
Lesinurad DMUR64T Moderate Increased metabolism of Fosamprenavir caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [42]
TP-434 DM5A31S Minor Decreased metabolism of Fosamprenavir caused by TP-434 mediated inhibition of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [72]
Suvorexant DM0E6S3 Major Decreased metabolism of Fosamprenavir caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [73]
Amobarbital DM0GQ8N Moderate Increased metabolism of Fosamprenavir caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [42]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Fosamprenavir caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [74]
ITI-007 DMUQ1DO Major Decreased metabolism of Fosamprenavir caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [75]
Quazepam DMY4D87 Moderate Decreased metabolism of Fosamprenavir caused by Quazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [76]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Fosamprenavir caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [77]
Naloxegol DML0B41 Major Decreased metabolism of Fosamprenavir caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [37]
Pemigatinib DM819JF Major Decreased metabolism of Fosamprenavir caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [43]
Crizotinib DM4F29C Major Decreased metabolism of Fosamprenavir caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [37]
Brigatinib DM7W94S Major Decreased metabolism of Fosamprenavir caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [78]
Ceritinib DMB920Z Major Decreased metabolism of Fosamprenavir caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [37]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Fosamprenavir caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [79]
PF-06463922 DMKM7EW Moderate Increased metabolism of Fosamprenavir caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [42]
Osimertinib DMRJLAT Major Decreased metabolism of Fosamprenavir caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [80]
BIBW 2992 DMTKD7Q Moderate Accelerated clearance of Fosamprenavir due to the transporter induction by BIBW 2992. Lung cancer [2C25] [81]
Pralsetinib DMWU0I2 Major Decreased metabolism of Fosamprenavir caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [82]
Capmatinib DMYCXKL Major Decreased metabolism of Fosamprenavir caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [83]
Selpercatinib DMZR15V Major Decreased metabolism of Fosamprenavir caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [43]
Artemether DM48QOT Major Decreased metabolism of Fosamprenavir caused by Artemether mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [37]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Fosamprenavir caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [37]
Idelalisib DM602WT Moderate Decreased metabolism of Fosamprenavir caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [84]
GDC-0199 DMH0QKA Major Decreased metabolism of Fosamprenavir caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [37]
IPI-145 DMWA24P Moderate Decreased metabolism of Fosamprenavir caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [85]
Acalabrutinib DM7GCVW Major Decreased metabolism of Fosamprenavir caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [86]
Ibrutinib DMHZCPO Major Decreased metabolism of Fosamprenavir caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [87]
Ponatinib DMYGJQO Major Decreased metabolism of Fosamprenavir caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [37]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Fosamprenavir caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [88]
Selumetinib DMC7W6R Major Decreased metabolism of Fosamprenavir caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [89]
Dabrafenib DMX6OE3 Moderate Decreased metabolism of Fosamprenavir caused by Dabrafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [37]
Ubrogepant DM749I3 Moderate Decreased metabolism of Fosamprenavir caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [90]
Rimegepant DMHOAUG Moderate Decreased metabolism of Fosamprenavir caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [91]
Exjade DMHPRWG Moderate Decreased metabolism of Fosamprenavir caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [92]
Flibanserin DM70DTN Major Decreased metabolism of Fosamprenavir caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [93]
Panobinostat DM58WKG Moderate Decreased metabolism of Fosamprenavir caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [94]
Siponimod DM2R86O Major Decreased metabolism of Fosamprenavir caused by Siponimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [37]
Deflazacort DMV0RNS Major Decreased metabolism of Fosamprenavir caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [43]
Romidepsin DMT5GNL Moderate Decreased metabolism of Fosamprenavir caused by Romidepsin mediated inhibition of CYP450 enzyme. Mycosis fungoides [2B01] [95]
Fedratinib DM4ZBK6 Major Decreased metabolism of Fosamprenavir caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [43]
Nilotinib DM7HXWT Major Decreased metabolism of Fosamprenavir caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [37]
Ruxolitinib DM7Q98D Major Decreased metabolism of Fosamprenavir caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [96]
Vorapaxar DMA16BR Major Decreased metabolism of Fosamprenavir caused by Vorapaxar mediated inhibition of CYP450 enzyme. Myocardial infarction [BA41-BA43] [37]
Netupitant DMEKAYI Minor Decreased metabolism of Fosamprenavir caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [97]
Entrectinib DMMPTLH Major Decreased metabolism of Fosamprenavir caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [37]
S-297995 DM26IH8 Moderate Decreased metabolism of Fosamprenavir caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [43]
Olaparib DM8QB1D Major Decreased metabolism of Fosamprenavir caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [37]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Fosamprenavir caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [98]
Istradefylline DM20VSK Major Decreased metabolism of Fosamprenavir caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [99]
Pimavanserin DMR7IVC Major Decreased metabolism of Fosamprenavir caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [100]
Abametapir DM2RX0I Moderate Decreased metabolism of Fosamprenavir caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [101]
Lefamulin DME6G97 Major Decreased metabolism of Fosamprenavir caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [102]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Fosamprenavir caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [103]
ABIRATERONE DM8V75C Minor Decreased metabolism of Fosamprenavir caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [104]
Enzalutamide DMGL19D Moderate Increased metabolism of Fosamprenavir caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [42]
Darolutamide DMV7YFT Minor Decreased metabolism of Fosamprenavir caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [105]
Silodosin DMJSBT6 Major Decreased metabolism of Fosamprenavir caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [37]
Ambrisentan DMD1QXW Minor Decreased metabolism of Fosamprenavir caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [106]
Riociguat DMXBLMP Moderate Decreased metabolism of Fosamprenavir caused by Riociguat mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [37]
Everolimus DM8X2EH Major Decreased clearance of Fosamprenavir due to the transporter inhibition by Everolimus. Renal cell carcinoma [2C90] [37]
Axitinib DMGVH6N Major Decreased metabolism of Fosamprenavir caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [37]
Ciclesonide DM2NA4K Moderate Decreased metabolism of Fosamprenavir caused by Ciclesonide mediated inhibition of CYP450 enzyme. Respiratory system disease [CB40-CB7Z] [107]
Upadacitinib DM32B5U Major Decreased metabolism of Fosamprenavir caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [108]
Tofacitinib DMBS370 Major Decreased metabolism of Fosamprenavir caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [37]
Iloperidone DM6AUFY Major Decreased metabolism of Fosamprenavir caused by Iloperidone mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [109]
Avanafil DM75CXN Major Decreased metabolism of Fosamprenavir caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [110]
Voxelotor DMCS6M5 Major Decreased metabolism of Fosamprenavir caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [111]
LDE225 DMM9F25 Major Decreased metabolism of Fosamprenavir caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [112]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Fosamprenavir caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [43]
Larotrectinib DM26CQR Major Decreased metabolism of Fosamprenavir caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [37]
Trabectedin DMG3Y89 Major Decreased metabolism of Fosamprenavir caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [37]
Armodafinil DMGB035 Moderate Increased metabolism of Fosamprenavir caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [64]
LEE011 DMMX75K Major Decreased metabolism of Fosamprenavir caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [43]
Pitolisant DM8RFNJ Moderate Increased metabolism of Fosamprenavir caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [43]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Fosamprenavir caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [37]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Fosamprenavir caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [113]
As-1670542 DMV05SW Moderate Decreased metabolism of Fosamprenavir caused by As-1670542 mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [43]
Apixaban DM89JLN Moderate Decreased metabolism of Fosamprenavir caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [43]
Brilinta DMBR01X Moderate Decreased metabolism of Fosamprenavir caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [43]
Cabozantinib DMIYDT4 Major Decreased metabolism of Fosamprenavir caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [37]
Saxagliptin DMGXENV Moderate Decreased metabolism of Fosamprenavir caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [43]
Elagolix DMB2C0E Moderate Increased metabolism of Fosamprenavir caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [42]
Fluticasone DMGCSVF Major Decreased metabolism of Fosamprenavir caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [114]
⏷ Show the Full List of 139 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Hypromellose E00634 Not Available Coating agent
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Fosamprenavir 700 mg tablet 700 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Approved antiretroviral drugs. Antiretroviral Drugs. Company report of AVERT. 2009.
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in ... J Antimicrob Chemother. 2009 Aug;64(2):398-410.
7 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
8 Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006;45(2):137-68.
9 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
10 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
11 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
12 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
13 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
14 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
15 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
16 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
17 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
18 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
19 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
20 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
21 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
22 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
23 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
24 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
25 PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008 Dec;80(12):2053-63.
26 Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liq... J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):575-80.
27 Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009 Apr;33(4):307-20.
28 Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacod... J Infect Dis. 2001 Apr 1;183(7):1126-9.
29 Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503.
30 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
31 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
32 2011 Pipeline of Boehringer Ingelheim Pharma.
33 2011 Pipeline of Bristol-Myers Squibb.
34 2011 Pipeline of InterMune.
35 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
36 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
37 Cerner Multum, Inc. "Australian Product Information.".
38 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
39 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
40 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
41 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
42 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
43 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
44 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
45 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
46 Polk RE, Crouch MA, Israel DS, et al. "Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men." Pharmacotherapy 19 (1999): 1378-84. [PMID: 10600086]
47 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
48 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
49 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
50 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
51 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
52 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
53 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
54 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
55 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
56 Product Information. Breo Ellipta (fluticasone-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
57 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
58 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
59 Product Information. Fetzima (levomilnacipran). Forest Pharmaceuticals, St. Louis, MO.
60 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
61 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
62 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
63 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
64 Barry M, Gibbons S, Back D, Mulcahy F "Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations." Clin Pharmacokinet 32 (1997): 194-209. [PMID: 9084959]
65 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
66 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
67 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
68 Product Information. Lexiva (fosamprenavir). GlaxoSmithKline, Research Triangle Park, NC.
69 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
70 Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir). Gilead Sciences, Foster City, CA.
71 Canadian Pharmacists Association.
72 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
73 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
74 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
75 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
76 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
77 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
78 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
79 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
80 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
81 Product Information. Gilotrif (afatinib). Boehringer Ingelheim, Ridgefield, CT.
82 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
83 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
84 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
85 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
86 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
87 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
88 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
89 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
90 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
91 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
92 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
93 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
94 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
95 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
96 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
97 Product Information. Akynzeo (netupitant-palonosetron). Eisai Inc, Woodcliff Lake, NJ.
98 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
99 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
100 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
101 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
102 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
103 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
104 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
105 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
106 Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
107 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
108 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
109 Product Information. Fanapt (iloperidone). Vanda Pharmaceuticals Inc, Rockville, MD.
110 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
111 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
112 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
113 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
114 Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]